International Immunopharmacology · Nov 17, 2026

Precision immunopharmacology in xenotransplantation: integrating genome-engineered donors, organoid testbeds, and AI-guided translation

By Ren T, Fu G, Duan S et al.

Xenotransplantation is moving from isolated proof-of-concept procedures toward an engineered biotechnology platform for organ replacement. This review examines how genome-designed donor pigs, recipient-directed immunopharmacology, human-relevant in vitro testbeds, and data-driven decision systems can be integrated to address the remaining barriers to clinical translation. CRISPR-Cas-based engineering enables deletion of dominant carbohydrate xenoantigens, insertion of human complement- and coagulation-regulatory genes, modulation of innate and adaptive immune checkpoints, control of donor-organ growth, and inactivation of porcine endogenous retrovirus sequences. However, donor engineering does not eliminate residual T-cell, B-cell, antibody, complement, natural killer (NK) cell, macrophage, and inflammatory responses. Contemporary immunopharmacological strategies therefore increasingly combine costimulation blockade with complement inhibition, lymphocyte-directed therapy, and selected cytokine- or innate-immune interventions, with future regimens requiring closer integration of pharmacokinetic and pharmacodynamic monitoring with donor genotype and organ-specific risk. Organoids and microfluidic vascular systems may provide an intermediate testing layer by quantifying antibody binding, complement activation, endothelial injury, coagulation, leukocyte transmigration, cytokine responses, and tissue-specific function under controlled conditions before escalation to large-animal studies. Artificial intelligence may further support xenoantigen discovery, genome-editing design, donor–recipient matching, multimodal rejection surveillance, and ultimately clinician-supervised immunopharmacological decision support. We propose that these components should be connected through a traceable design-build-test-learn workflow linking computational prediction, donor construction, standardized functional testing, non-human-primate validation, and early human data. Durable translation will depend not on any single technological advance, but on reproducible donor manufacturing, precision immune control, validated human-relevant test systems, standardized longitudinal data, pathogen surveillance, organ-specific management, and transparent regulatory governance.

doi.org/10.1016/j.intimp.2026.117691PubMed 43044535Interventions

AgingResearch.News